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Background: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit
personalized therapy. Identifying the genetic profile of patients with acute coronary syn-
drome (ACS) who are considered for therapy with clopidogrel (P2Y12 receptor blockers) and
acetylsalicylic acid (ASA) contributes to the treatment paradigm. Patient preferences would
inform a collaborative framework and by extension inform healthcare policy formulation.
Purpose: To quantify stated preferences (willingness to pay) for attributes of a novel point-of-
care PGx (CYP2C19) test using a discrete choice experiment (DCE) from the general public in
Ontario, Canada, and to identify starting point bias of the cost attribute.
Methods: A web survey was created and included a questionnaire, decision board, and
a DCE. DCE choice sets include the following attributes (levels): sample collection (blood,
finger prick, and cheek swab), turnaround time for results (1 hr, 3 days, and 1 week), and cost
in additional insurance premiums. The presence of starting point bias (cost attribute levels of
$0, $1, $5 or $0, $2, $10) in the estimation of willingness to pay (WTP) was tested.
Results: Estimates for turnaround time and cost attributes were statistically significant.
Coefficients related to the starting point bias were also significant. Approximately 67% of survey
participants chose the PGx test compared to status quo treatment options. WTP for a 1 hr turn-
around time compared to a 1-week turnaround time was $10.77 (95% CI 9.58 -12.25).
Conclusion: This translational study shows preference for a point of care PGx test.
Keywords: discrete choice experiment, pharmacogenetic test, patient preference, starting
point bias
Introduction
The United States Food and Drug Administration (FDA) had issued a warning
related to the safety of clopidogrel prescribed to patients with a reduced or loss-of-
function (LOF) CYP2C19 allele; stating that
poor metabolizers treated with (clopidogrel) at recommended doses exhibit higher
cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous
coronary intervention (PCI) than patients with normal CYP2C19 function.1
In a 2011 publication, the Canadian Cardiovascular Society (CCS) recommended com-
bination therapy with clopidogrel (P2Y12 receptor blockers) and acetylsalicylic acid
(ASA) to prevent ischemic complications in patients suffering an ACS and to those
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undergoing PCI.2 In an updated guideline, the CCS recom-
mended that dual antiplatelet therapy with ASA 81 mg daily
and either ticagrelor 90 mg twice daily or prasugrel 10 mg
once daily over clopidogrel 75 mg once daily for 1 year be
prescribed to patients suffering an ACS and to those under-
going PCI.3
Absent from these recommendations is the option of
using pharmacogenetic (PGx) testing for either the wild
type CYP2C19 allele or the CYP2C19 heterozygous and
homozygous *2 and *3 reduced function allele to determine
a patient’s genetic profile and thus help determine the
appropriate treatment option. Over the past few years, sev-
eral trials have been designed to evaluate whether selecting
antiplatelet therapy (clopidogrel, prasugrel, or ticagrelor)
based on patient’s genetic characteristics leads to better
clinical outcomes compared with the standard of care.4,5
In one of these trials, for example, the primary objective of
the Tailored Antiplatelet Therapy Following PCI (TAILOR-
PCI) trial was to measure the occurrence of major adverse
cardiovascular events (MACE) after PCI. The estimated
study completion date is March 2020.4
PGx tests have evolved over the last several years.
Specifically, a next-generation PGx test analyzes patient
samples at the point of care (POC);6 thus, eliminating the
need to batch and send the sample to a laboratory for
analysis. Moreover, results from the novel test are available
to the clinician within 1 hr, compared to the 2–7 days
required using other CYP2C19 tests. Finally, the newer
PGx test enables health-care personnel with no previous
training in genetic laboratory techniques to undertake
genotyping.6
A proof of concept study of a novel point-of-care
genetic test was carried out to accurately identify carriers
of the CYP2C19*2 allele, which subsequently permitted
carriers to be switched to the appropriate P2Y12 receptor
blocker drug; thus enabling a pharmacogenetic approach
to dual antiplatelet treatment after PCI. The study gener-
ated results with a sensitivity of 100% (95% CI 92.3–-
100%) and a specificity of 99.3% (95% CI 96.2–100%).7
This novel point-of-care genetic test was used as
a therapeutic option in our study.
Collaborative (ie, patient, health-care provider) deci-
sion-making frameworks have been developed to help facil-
itate the delivery of care.8 Patient preferences may help
inform this framework and by extension inform healthcare
policy formulation. In health care, patient preferences may
be elicited through stated preference techniques such as
discrete choice experiments (DCE).9 In a DCE, participants
are asked to choose between two or more scenarios. If a cost
component is included in the choice set, the ensuing data
may be used to calculate a willingness to pay (WTP) value
and in turn inform economic evaluations.
Survey studies that contain a cost component are subject
to starting point bias. Starting bias suggests that respondents
to the survey are influenced by the initial cost point they are
asked to consider within the survey. This study sought to
quantify the elicited preferences and evidence of starting
point bias for the genetic test cost attributes. A WTP was
derived from stated preferences.
Methods
The complete design of the DCE survey (including screen-
shots) was submitted for ethics approval. This study was
approved by the Office of Research Ethics at the
University of Toronto (Protocol reference # 31225).
A web-based survey was created by the authors, then
distributed through a private market research firm (EKOS
Research Associates) by emailing invitations to potential
respondents.10 EKOS Research Associates was asked to
stratify the target population to age, gender, and education
based on the Canadian National Household survey (2011).
Stratification was requested to align similar demographic
attributes of the Ontario population to that of the survey
respondents. The target population included both potential
“users” and “non-users” of the PGx test from the general
population in Ontario (Canada). The potential “user”
population were individuals who would be informed by
their physician that they would be at risk for ACS. “Non-
users” were individuals who may want the product avail-
able even though they have no intention of purchasing it
now or currently do not exhibit any risk factors listed
for ACS.
In addition to a consent form and a demographic ques-
tionnaire, the electronic survey included descriptions of clin-
ical conditions, a decision board, and a DCE. The clinical
descriptions (ACS, MACE, and genetic testing) were based
on patient advocacy web sites and patient information sheets
provided by the University of Ottawa Heart Institute.11
A decision board was created to inform participants about
the risks associated with three treatment options. (Figure 1).
The adverse events communicated to the participant were
MACE and bleeding. After reviewing the decision board,
participants were asked to choose between the three gener-
ically labelled treatment options. Treatment A reflected the
clinical outcomes of the status quo option (ie, universal
clopidogrel). Treatment B represented the clinical outcomes
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of treatment with either prasugrel or ticagrelor. Treatment
C represented the clinical outcomes of a PGx option where
subjects who are non-carriers of loss of function
(LOF) allelesare prescribed clopidogrel and LOF carriers
are prescribed either prasugrel or ticagrelor.
Three rates of MACE and bleeds were required to inform
the Decision Board: Treatment optionA, Treatment option B,
and Treatment option C. Rates for treatment option A and
B were retrieved from two head-to-head randomized con-
trolled studies (TRITON-TIMI-3812 study and PLATO13).
Rates for Treatment option C were taken from genetic sub-
studies14–16 from the respective trials.
The TRITON-TIMI-38 compared efficacy and safety
endpoints between clopidogrel and prasugrel; while the
PLATO trial compared clopidogrel with ticagrelor. The
rates of MACE are similar for clopidogrel compared to
either prasugrel (12.10% vs 9.90%; p<0.001) or ticagrelor
(11.70% vs 9.80%; p<0.001) trials. Since MACE and bleed
rates were represented using face emojis (Figure 1), whole
numbers needed to be used to represent the respective
efficacy and safety rates. As such that the numbers were
rounded to 12% (Treatment A) and 10% (Treatment B).
Genetic sub-studies reported the rates of MACE by CYP
polymorphism. Under the PGx option in the Decision Board
(Treatment C), clopidogrel was prescribed to subjects with
fully functional CYP2C19*2 allele, and either prasugrel or
ticagrelor was prescribed to patients who carry a LOF
CYP2C19*2 allele. The rate of MACE for Treatment C was
based on the MACE rates by polymorphism for each drug
and weighed by the proportion of either fully functional or
LOF carriers to the total study population. The proportion of
LOF carriers was similar in both the TRITON and PLATO
genetic sub-studies (28%). As such, the rate of subjects with
fully functional alleles was 72%. Therefore, MACE rate for
the PGx option is 8.14% (28%*8.50% + 72%*8.00%) using
the TRITON genetic sub-study and slightly higher at 8.60%
(28%*9.40%+ 72%*8.30%) based on the PLATO sub-study.
Conservatively, the rate of MACE under the PGx option will
be rounded up to 9.
Through inference, survey participants who chose
Treatment option A or B rejected the PGx treatment
option. (By extension, these participants would not be
willing to pay any price for the PGx treatment option,
this proportional value was incorporated into quantifying
the population level WTP). Alternatively, participants who
chose Treatment C inferred that they were hypothetically,
willing to consider a PGx test in their treatment algorithm,
presumably to avoid the MACE and bleeding. As such,
Figure 1 Screenshot: Decision board highlighting the available treatment options.
Abbreviation: MACE, major adverse cardiovascular event.
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only participants choosing Treatment option “C” were
directed to complete the DCE. The purpose of the DCE
was to elicit preference values for attributes of a PGx test.
Participants in the DCE were presented with 8 choice
sets. Each choice set described two hypothetical PGx tests,
labelled generically “Choice A” or “Choice B” (Figure 2).
Each choice set represented a different combination of
attributes for a PGx test. Attributes of a PGx test was
derived from a description of the next generation pharma-
cogenetic test6 and a literature review. In addition, an
expert panel including a cardiologist, pharmacists, and
health economist was convened to validate the attributes
and attribute levels. It is likely that the DCE did not
include every attribute important to every participant.
However, the literature review and the face validation
process (as provided by the convened expert panel) likely
captured attributes that were relevant to most of the survey
participants.
Attributes (attribute levels) for each choice set were
sample extraction (blood draw, finger prick, cheek swab),
turnaround time for results (1 hr, 3 days, and 1 week) and
cost. In Ontario, Canada, the payment mechanism for
most health-care services at the point of consumption is
through an insurance system. As such, the cost attribute
was asked in the context of hypothetical insurance
purchasing.17 Two versions of choice sets were created
that reflected additional insurance premiums. Version 1
showed cost levels of $0, $1, and $5 and Version 2
showed cost levels of $0, $2, and $10. (Additional insur-
ance premium values were chosen based on expert opi-
nion, personal communication with Prof. Doug Coyle,
University of Ottawa) Survey participants were randomly
allocated to one of these versions. The purpose of this
process was to measure starting point bias within a DCE.
Given three attributes, each with three levels; the total
number of possible scenarios is 27 (33) each representing
a unique product. Once each of the 27 unique choices were
identified, choice sets were constructed by grouping two of
the 27 unique choices to make up one set. This was
accomplished using a random generator in Excel.18 Eight
choice sets were randomly selected for each survey parti-
cipant. A full factorial design was used which allows for
estimation of all main effects (effect of each attributes) and
interaction effects (effect of interaction between two or
more attributes) independently of one another.9
Regression analysis was generated using SAS software
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Specifically, a BCHOICE procedure was used within
SAS software to run a Bayesian regression analysis for
the discrete choice model. A conditional logit method was
Figure 2 Screenshot: Choice set example.
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used to estimate the frequentist fixed effects regression.
The logit model with random effects was also specified to
consider the multiple observations from each participant.
Inter-participant variation was dealt within the design of
the DCE, as each participant was presented with eight
randomly generated choice sets.
Willingness to pay (WTP) for each level of a given attri-
bute was calculated by dividing the negative of the estimated
β coefficient for each attribute by the coefficient of cost.19
Income effect on WTP was also estimated. The maximum
WTP for a change in turnaround time from 0 to 1 in terms of
money (cost) was quantified by forming the ratio of the
marginal utilities where the marginal utility of Turnaround
time is βTurnaround time and the marginal utility of cost = - βCost
thus the maximumwillingness to pay for a turnaround time of
1 hr instead of 1 week is - βTurnaround time/βCost. Similarly, the
marginal utility of the sample is βSample and the marginal
utility of cost = -β3 thus the maximum willingness to pay
for a specific sample method is – βSample/βCost.
In effect, survey participants were asked to consider
trading off attribute levels for money. For example, we
quantified a WTP value that reflects the incremental amount
individuals would be willing to pay between a blood draw
and a cheek swab or between a finger prick and a cheek
swab. WTP was also quantified for how much more indivi-
duals would be willing to pay between getting result in 1 hr
compared to 1 week; or between 1 hr or 3 days.
An interaction term was added to the regression model
with the purpose of determining the starting point bias in
the DCE. For the cost attribute, approximately half of the
study sample was allotted to the version where the cost
attribute levels were $0, $1, $5 and the other half to the
version where the cost attribute levels were $0, $2, and
$10. The interaction term would help determine whether
an interaction effect exists between the group that was
provided the lower cost attribute levels in the DCE and
the group that was provided higher levels in the DCE.
A significant interaction effect would mean that there are
significant differences between the two groups.
Sample size was dictated by numbers of choice sets
and number of versions.19 Empirical evidence suggests
that 20 participants per group of choice sets are sufficient
to estimate reliable models.19 Given this assumption, and
based on 8 choice sets, the sample size was estimated to be
8X20 = 160 participants. Given that we are also measuring
starting point bias with two sets of costs the final sample
size target was 320 participants.
Results
E-mail invitations were sent to 4,234 panel members regis-
tered with EKOS. Of these, 387 initiated and 329 indivi-
duals completed the survey. Table 1 presents the
demographic characteristics of the DCE survey participants
and compares the survey demographic to that of the pro-
vince of Ontario in 2011. The survey sample size under-
represented the under 25 years of age category and those
with a bachelor’s degree and over-represented those with
a graduate degree and households with an income of over
$100,000 (CDN). The male:female proportion of the parti-
cipants in this survey is similar to that of the 2011 Statistics
Canada Census figures for Ontario. With the exception of
the under 25-year-old age bracket, proportion of other age
brackets is also similar to the 2011 Census.
Of the 329 who completed the survey, 66.8% of parti-
cipants chose the PGx treatment option. The one-hour
attribute level was preferred to longer wait times (statisti-
cally significant). However, the cheek swab method was
Table 1 Survey Demographics and Comparison to Ontario
Population

























100,000 + 42.6 29.5
Note: *Canadian dollars.
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preferred to both the finger prick or blood draw (though
this was not statistically significant). Results from regres-
sion analysis are presented in Table 2.
Coefficients for the starting point bias were statistically
significant. This coefficient (standard deviation) [95%
Highest posterior density interval] using Bayesian random
effects was 0.2268 (0.0354) [0.1557–0.2936] and 0.5481
(0.1483)[0.2583–0.8386] for the fixed effect. The frequen-
tist result (standard error) was 0.2254 (0.0357) and was
significant (<0.0001). These values suggest that starting
point bias exists for this DCE.
The odds that a participant chose the 1 hr turnaround time
was 14 times that of the 1-week turnaround time (23 times for
Version 1: with cost values of $0, $1, $5; 12 times for Version
2: with cost values of $0, $2, $10).
Table 3 presents possible predictors of choosing
a specific cost level by sex, having private insurance, his-
tory with side effects, previous genetic testing, and income.
Results are presented using the entire sample and from the
frequentist, fixed and random effects approaches used for
analysis. Predictors of cost levels chosen were having insur-
ance, having experience with reacting badly to medication,
having a family income of between $50,000 and $149,999
and having history of genetic testing. Sex and having an
income of less than $50,000 or over $150,000 were not
predictors of cost levels chosen.
Table 2 Summary of Coefficient Estimates Using: Bayesian Fixed Effects, Bayesian Random Effects, and Frequentist Approaches














Cost −0.2451 0.0153 −0.2739 −0.2146 −0.7461 0.0752 −0.8999 −0.6053 −0.2438 0.0152 <0.0001
Turnaround time 1_hour 2.6370 0.1420 2.3703 2.9186 7.1797 0.7328 5.8295 8.6687 2.6267 0.1403 <0.0001
Turnaround time 3_days 1.0751 0.1121 0.8470 1.2839 2.9947 0.4287 2.1727 3.8181 1.0722 0.1105 <0.0001
Sample Blood draw 0.0826 0.1043 −0.1210 0.2811 0.4357 0.2938 −0.1609 0.9883 0.0838 0.1044 0.4225
Sample Finger_prick −0.0119 0.1070 −0.2188 0.1968 0.1356 0.2386 −0.3193 0.6126 −0.0147 0.1076 0.8912
Choice version ($0, $1, $5)
Cost −0.4682 0.0401 −0.5451 −0.3859 −1.4460 0.2076 −1.8643 −1.0589 −0.4632 0.0395 <0.0001
Turnaround time 1_hour 3.1676 0.2515 2.6787 3.6624 9.8536 1.4948 7.1650 12.8915 3.1373 0.2454 <0.0001
Turnaround time 3_days 1.3833 0.1842 0.9945 1.7158 4.2123 0.8407 2.6782 5.9110 1.3717 0.1792 <0.0001
Sample Blood draw 0.3333 0.1678 0.0100 0.6599 1.1999 0.5608 0.0620 2.2501 0.3325 0.1664 0.0458
Sample Finger_prick 0.00596 0.1676 −0.3187 0.3335 0.1591 0.4051 −0.5952 0.9800 0.00161 0.1672 0.9923
Choice version ($0, $2, $10)
Cost −0.1978 0.0161 −0.2278 −0.1648 −0.6890 0.1059 −0.9101 −0.4974 −0.1961 0.0159 <0.0001
Turnaround time 1_hour 2.5107 0.1849 2.1582 2.8676 7.5754 1.1469 5.6197 10.0052 2.4935 0.1815 <0.0001
Turnaround time 3_days 0.9510 0.1491 0.6541 1.2348 3.0076 0.6661 1.8125 4.3317 0.9464 0.1464 <0.0001
Sample Blood_draw −0.0741 0.1375 −0.3447 0.1860 −0.0506 0.4360 −0.9120 0.7885 −0.0715 0.1371 0.6018
Sample Finger_prick 0.0103 0.1445 −0.2602 0.2976 0.000390 0.4094 −0.7665 0.8510 0.00702 0.1455 0.9615
Table 3 Demographic Predictors of Choosing a Cost Attribute (Full Sample Set)
Parameter Frequentist Bayesian Random Effects Bayesian Fixed Effects
Estimate Pr > ChiSq Mean 95% HPD Interval Mean 95% HPD Interval
Sex 0.00873 0.7576 0.0399 −0.2552 0.3259 0.00880 −0.0469 0.0645
Insurance −0.1547 <0.0001 −0.4577 −0.8248 −0.1127 −0.1569 −0.2322 −0.0818
Reacted Badly 0.0802 0.0068 0.2762 −0.0121 0.5781 0.0817 0.0221 0.1407
Income <50,000 −0.0530 0.1494 −0.1863 −0.5449 0.1941 −0.0549 −0.1253 0.0200
Income 50,000–99,999 −0.0695 0.0309 −0.1069 −0.4250 0.2115 −0.0708 −0.1319 −0.00621
Income 100,000–149,999 −0.1237 0.0303 −0.3252 −1.0116 0.2885 −0.1306 −0.2463 −0.0135
Income 150,000 + −0.0464 0.2780 0.00928 −0.4409 0.4576 −0.0481 −0.1343 0.0377
Prior Test 0.1557 0.0442 0.5257 −0.3188 1.3509 0.1586 0.0103 0.3203
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Willingness to pay values for all attributes are presented
in Table 4. From a frequentist approach, WTP (95% con-
fidence interval) for a 1 hr turnaround time compared to a 1
week turnaround time was $10.77 (95%CI 9.58-12.25),
$6.77 (95%CI 5.82-7.91), and 12.72 (95%CI 10.82-15.01)
for the entire data set, Version 1 and Version 2, respectively.
WTP values were slightly lower when using coefficients
from the random effects approach for the entire data set, as
well as for the $0,2,10 set. For the $0,1,5 set, WTP values
were similar to slightly higher for turnaround time. As
expected, the value for the incremental cost of choosing
a 1 hr turnaround time was lower when the 3-day turn-
around time was presented than the 1-week turnaround
time.
Discussion
The primary focus of this study was to quantify prefer-
ences for attributes of a PGx test and identify whether
a starting point bias exists in this DCE. The secondary
objective was to determine a WTP for a PGx test, whose
value could be used to inform economic evaluations.
Approximately two-thirds of survey participants chose
the PGx treatment option. Furthermore, those surveyed
were 14 times more likely to choose shorter turnaround
times and the cheek swab method of sample extraction
over either the finger prick method or blood draw. The
direction of the coefficients from the regression analysis
was as expected, regardless of the method approach chosen.
The direction of the coefficients indicated that survey parti-
cipants understood the urgency of the possible adverse
events and the importance of being treated with the appro-
priate medication given their genetic (CYP2C19) status.
The survey invited both potential “users” and “non-
users” of the POC PGx test to participate in the survey. By
doing so, the survey may have captured possible ‘family
spillover benefits. Spillover benefits are an effect where
“non-users”would deem a benefit from someone else (family
member, friend) using the PgX test.
Of note is that there is a possibility that survey
responses did not consider the constraints of their own
budgets or incomes. The initial survey questionnaire did
not capture participants’ ability to pay for their choices or
whether the cost attribute fit into their budget. The ques-
tion that was asked of the participant is how much more
they are willing to spend in annual health insurance pre-
miums in exchange for coverage of the PGx test. This
question pre-supposes that participants were aware of
their current level of health insurance premium expendi-
ture. It should be noted that no studies have been located
that shed light on this particular aspect of consumer aware-
ness. However, providing a national average of individual
expenditures for health insurance premiums prior to the
survey may have been helpful for the participant.
Furthermore, knowing this amount would have provided
Table 4 Summary of Willingness to Pay Estimates: Bayesian Fixed Effects, Bayesian Random Effects, and Frequentist Approaches
Parameter Bayesian Fixed Effects Bayesian Random Effects Frequentist
WTP C$ WTP C$ WTP C$
Entire Data Set
Turnaround time 1_hour vs 1 week 10.75 (9.48, 12.22) 9.62 (7.91, 11.75) 10.77 (9.58, 12.25)
Turnaround time 3_days vs 1 week 4.38 (3.44, 5.36) 4.01(2.98, 5.16) 4.40 (3.50, 5.42)
Sample Blood_cheek swab vs blood 0.34 (−0.50, 1.17) 0.58 (−0.20, 1.38) 0.34 (−0.47, 1.18)
Sample Finger_prick vs blood −0.05 (−0.92, 0.80) 0.18 (−0.45, 0.83) −0.06 (−0.95, 080)
Choice version ($0, $1, $5)
Turnaround time 1_hour vs 1 week 6.77 (5.81, 7.99) 6.81(5.23, 8.81) 6.77 (5.82, 7.91)
Turnaround time 3_days vs 1 week 2.95 (2.19, 3.78) 2.91(1.90, 4.07) 2.96 (2.21, 3.78)
Sample Blood_cheek swab vs blood 0.71 (0.00, 1.44) 0.83 (0.04, 1.50) 0.72 (0.01, 1.44)
Sample Finger_prick vs blood 0.01(−0.71, 0.74) 0.11 (−0.45, 0.72) 0.00 (−0.72, 0.72)
Choice version ($0, $2, $10)
Turnaround time 1_hour vs 1 week 12.69 (10.81, 14.95) 10.99 (8.31, 14.75) 12.72 (10.82, 15.01)
Turnaround time 3_days vs 1 week 4.37 (3.26, 6.42) 4.37 (2.71, 6.34) 4.83 (3.44, 6.44)
Sample Blood_cheek swab vs blood −0.37(−0.82, 1.02) −0.07 (−1.42, 1.19) −0.36 (−1.73, 1.01)
Sample Finger_prick vs blood 0.05 (−1.45, 1.49) 0.00 (−1.23, 1.18) 0.04 (−1.44, 1.42)
Abbreviation: WTP C$, Willingness to pay in Canadian dollars.
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the basis of creating the attribute levels for the cost com-
ponent of the DCE.
It should be noted that not all possible attributes were
included in the survey. For example, the attribute of offer-
ing a separate cohort of trained technicians to interpret the
results was not included in the choice sets. The novel PGx
POC test would have required a brief training of clinicians
and not a separate resource to interpret test results. This
particular attribute may have been more relevant if the DCE
was created to generate preferences from hospital adminis-
trators rather than the public. This was a survey sought to
elicit preferences from the general population. As such, this
attribute was left out.
While attributes other than cost were based on literature
and input from co-investigators, determining what values to
place on cost levels for the DCE was challenging. There was
little guidance available from literature to determine cost
attribute levels. This sentiment is shared by some in recent
literature.20 Furthermore, it has been pointed out that coming
up with cost attribute levels straddle a fine line between being
too low (and thus irrelevant to the survey participants) or too
high (thus being prohibitive).21 However, the concept of
what is “too low” or “too high” has not been elucidated in
literature. It should be noted that the Canadian market value
for the PGx POC test used as the basis for this study was
approximately C$125–150 per patient. Since the framework
of the research question was in terms of additional insurance
premiums in Canada, we reached out to insurance companies
to get a sense of what the market level would be for novel
technologies as they pertain to ACS. No response was pro-
vided. As such, we relied on expert opinion from academic
sources familiar with DCE content. (personal communica-
tion). While it can be argued that the cost levels were “too
low” in this study to be relevant, the existence of a starting
point bias suggests that survey participants were influenced
by the cost levels that were provided.
When identifying predictors of choosing a cost level,
there were several consistencies between the analytic
approaches. First, sex was not a predictor of choosing
a cost level. Furthermore, lower and upper bands of the
income levels were also not predictive of the cost levels
chosen. However, as expected, having insurance was
a predictor as well as previous exposure to adverse events.
Furthermore, analysis suggests that starting bias is
present. Researchers must make a viable case for the cost
values to be included in their DCEs. Erroneous cost levels
in a DCE may result in biased values for the willingness to
pay, rendering the resulting economic evaluations moot.
Another limitation is related to the attributes included
in the DCE. For example, from the initial questionnaire,
we know that some participants were concerned about
confidentiality and privacy issues related to the DCE.
Had there been an attribute that reflected privacy issues,
the resulting WTP may have varied from the reported
results. Furthermore, the novel POC PGx test would not
have needed additional training to operate and as such may
have provided some value to hospital administrators. This
feature was not measured for preference since hospital
staff were not surveyed.
Finally, no exit questions were asked of participants.
A question related to whether the increased cost was
affordable to their respective budget would have been
informative. Furthermore, open-ended question regarding
the ease of completing the survey, ease of understanding
the content, and the ease of completing the DCE would
have been informative for future DCE studies.
Despite the limitations, PGx testing is widely accepted
as an alternative treatment algorithm for ACS of PCI.
Under the collaborative decision framework, formulations
of health-care policy should take into consideration stated
preference studies. It should be noted that the results
reported here are specific to the attributes of this POC
PGx test described above and the underlying conditions
and adverse events described in the decision board.
Conclusions
Pharmacogenetic technology is a complex intervention (ie,
comprised of a number of related characteristics involving
a number of stakeholders). This study shows that survey
participants favoured rapid turnaround time for results
from PGx tests and were willing to pay for the incremental
safety and convenience.
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